smallpox
caus
infectionwith
variola
viru
one
deadli
diseasesin
human
histori
mortal
rate
fortun
diseas
complet
erad
throughout
world
introduct
global
smallpox
vaccin
campaign
process
vaccinia
viru
share
broad
antigen
properti
variola
viru
play
essenti
role
effect
vaccin
induc
protect
immun
smallpox
well
accept
vaccineinduc
neutral
antibodi
critic
protect
fear
variola
viru
deliber
releas
potenti
bioterror
attack
increas
use
vaccinia
vaccin
vector
diseas
aid
led
recent
studi
aim
understand
protect
immun
respons
induc
smallpox
vaccin
therefor
necessari
investig
neutral
antibodi
respons
induc
histor
use
smallpox
vaccin
via
differ
rout
vaccin
extens
use
smallpox
vaccin
china
vaccinia
viru
tiantan
vtt
strain
accordingli
origin
vtt
isol
skin
lesion
smallpox
patient
china
around
follow
extens
passag
time
monkey
rabbit
bovin
twice
rabbit
time
bovin
repeatedli
genet
analysi
vtt
genom
howev
suggest
vaccinia
strain
instead
variola
viral
variant
clinic
safeti
vaccin
clearli
document
although
vtt
histor
use
million
peopl
issu
essenti
safe
smallpox
vaccin
biolog
characterist
vtt
describ
recent
studi
report
vtt
caus
larger
lesion
intraderm
vaccin
like
virul
wide
use
smallpox
vaccin
lister
wyeth
date
whether
vtt
induc
protect
neutral
antibodi
respons
noninvas
mucos
vaccin
remain
less
understood
studi
vtt
investig
immunogen
term
induc
neutral
antibodi
four
differ
rout
vaccin
mous
model
previous
studi
moreov
conduct
homolog
heterolog
rout
viral
challeng
aim
determin
efficaci
vtt
protect
identifi
strategi
overcom
preexist
immun
vttbase
vaccin
studi
involv
safe
nonpathogen
viral
challeng
model
use
high
dose
modifi
vtt
name
mvtt
express
spike
glycoprotein
sarscov
sinc
express
surfac
vaccinia
viru
aim
determin
role
antivtt
neutral
antibodi
nab
respons
achiev
protect
evalu
seroconvers
result
implic
understand
aspect
vacciniainduc
protect
immun
develop
vacciniabas
vaccin
background
biolog
properti
smallpox
vaccin
vaccinia
tiantan
vtt
describ
previous
vtt
stock
propag
vero
cell
purifi
repeat
freez
thaw
centrifug
sucros
cushion
viral
pellet
subject
sucros
gradient
centrifug
purifi
virus
collect
studi
plaqu
form
unit
pfu
viral
stock
titrat
vero
cell
plaqueform
assay
use
crystal
violet
stain
construct
character
challeng
viru
mvtt
describ
previous
five
group
femal
balbc
mice
includ
studi
group
nine
mice
inocul
optim
dose
pfu
vtt
one
four
differ
rout
includ
intramuscular
im
intranas
oral
io
subcutan
sc
inocul
respect
anoth
group
nine
mice
receiv
placebo
control
measur
last
nab
respons
mice
kept
six
month
observ
test
six
month
observ
group
mice
divid
three
subgroup
subgroup
three
mice
challeng
dose
pfu
mvtt
one
three
differ
rout
includ
im
io
respect
highest
dose
possibl
mucos
challeng
base
concentr
viral
stock
size
anim
threeweek
interv
anim
challeng
dose
pfu
mvtt
blood
sampl
collect
week
week
week
week
measur
nab
respons
mvtt
challeng
anim
protocol
approv
institut
committe
laboratori
anim
use
wuhan
univers
sinc
mvtt
attenu
vtt
variant
lethal
mice
defin
full
protect
lack
detect
anti
nab
respons
induc
challeng
viru
mvtt
studi
pseudovirusbas
neutral
assay
appli
determin
humor
immun
respons
glycoprotein
sarscov
pseudotyp
viru
gener
cotransfect
cell
two
plasmid
carri
optim
gene
human
immunodefici
viru
type
backbon
respect
experi
pool
sera
contain
equal
amount
serum
vaccin
mous
group
subject
assay
describ
other
luciferas
activ
measur
perkinelm
victor
micropl
reader
accord
manufactur
instruct
comparison
serum
sampl
unvaccin
mice
experi
score
seroposit
valu
reach
serum
dilut
factor
valu
serum
dilut
factor
achiev
viral
inhibit
test
serum
neutral
activ
vtt
use
flowcytometrybas
assay
similar
previous
publish
method
assay
modifi
vtt
contain
gfp
mvttgfp
express
cassett
construct
briefli
neutral
activ
heatinactiv
sera
min
determin
mix
pfuml
vttgfp
viru
equal
amount
dilut
serum
h
incub
cell
ad
well
plate
incub
cell
dilut
use
cultur
medium
contain
fb
streptomycin
penicillin
cytosin
arabinosid
per
ml
hr
incub
infect
cell
wash
pb
twice
trypsin
trypsin
cell
pellet
wash
fix
paraformaldehyd
subsequ
subject
fac
analysi
titer
viral
neutral
determin
calcul
percent
reduct
infect
cell
show
gfp
posit
express
similarli
valu
serum
dilut
factor
achiev
viral
inhibit
student
ttest
use
evalu
statist
signific
nab
titer
among
variou
group
anim
origin
comput
softwar
use
analysi
studi
sought
determin
whether
vtt
would
induc
differ
level
nab
via
variou
rout
vaccin
critic
question
vtt
histor
use
smallpox
vaccin
million
peopl
yet
potenti
use
noninvas
vaccin
remain
elus
address
question
four
group
mice
inocul
optim
dose
pfu
vtt
via
sc
im
io
rout
respect
anoth
group
mice
receiv
placebo
control
three
week
inocul
anim
test
product
antivtt
nab
use
newli
develop
facsbas
mvttgfp
neutral
assay
figur
sinc
sampl
quantiti
small
pool
sera
test
experiment
group
pool
sera
contain
equal
amount
serum
individualmicein
eachgroup
found
rout
vaccin
abl
induc
antivtt
nab
respons
onetim
vaccin
figur
b
level
antivtt
nab
howev
vari
depend
rout
vaccin
appar
higher
level
nab
induc
via
io
inocul
compar
im
sc
rout
serum
dilut
factor
base
valu
via
differ
rout
io
im
sc
respect
order
measur
longlast
level
nab
gener
kept
separ
group
vaccin
anim
six
month
despit
virul
effect
vtt
eg
bodi
weight
chang
acut
phase
vaccin
mice
surviv
continu
observ
six
month
vaccin
serum
sampl
collect
subsequ
subject
neutral
assay
interestingli
although
significantli
improv
io
group
rest
three
group
mice
especi
group
develop
higher
level
last
antivaccinia
nab
compar
earli
time
point
figur
b
c
suggest
prolong
vttantigen
stimul
immun
system
serum
dilut
factor
base
valu
via
differ
rout
io
versu
im
sc
averag
versu
averag
respect
tabl
furthermor
higher
level
longlast
antivaccinia
nab
consist
found
io
group
compar
im
sc
group
figur
c
averag
valu
mucos
group
io
higher
im
sc
rout
versu
p
randomli
select
individualmiceof
group
test
consist
result
obtain
determin
longlast
efficaci
four
rout
vtt
vaccin
parallel
ten
group
vaccin
mice
challeng
mvtt
six
month
vaccin
mous
receiv
pfu
mvtt
highest
possibl
dose
base
viral
stock
via
io
rout
respect
mimic
natur
transmiss
variola
viru
sinc
anti
antibodi
detect
three
week
challeng
group
subsequ
gave
anoth
mvtt
challeng
dose
way
found
io
vtt
vaccin
protect
mice
significantli
homolog
io
mvtt
challeng
respect
without
anti
antibodi
detect
second
challeng
figur
tabl
lack
seroconvers
serv
biomark
protect
mvtt
infect
analyz
group
anim
found
io
vtt
vaccin
protect
mice
complet
heterolog
rout
io
mvtt
challeng
respect
without
detect
anti
nab
figur
contrast
mvtt
challeng
result
high
level
anti
nab
nonvaccin
mice
second
challeng
figur
valu
reach
serum
dilut
titer
moreov
im
vtt
vaccin
also
protect
mice
complet
io
mvtt
challeng
respect
figur
lack
detect
anti
nab
two
consecut
mvtt
challeng
like
suggest
possibl
complet
protect
figur
notabl
sc
vtt
vaccin
complet
protect
mice
io
mvtt
challeng
anti
antibodi
readili
detect
three
week
second
challeng
figur
b
sinc
mean
anti
titer
sc
vaccin
mice
significantli
lower
nonvaccin
control
versu
p
figur
b
specul
least
partial
signific
protect
achiev
sc
vtt
vaccin
p
valu
determin
compar
anti
mean
valu
sc
vaccin
group
averag
valu
versu
control
group
averag
valu
possibl
less
protect
sc
vaccin
mice
relat
lower
level
antivtt
neutral
antibodi
induc
figur
tabl
sinc
mvtt
caus
transient
viremia
infect
mice
recent
describ
effort
detect
live
challeng
viru
around
three
week
challeng
group
unsuccess
sinc
mucos
vtt
vaccin
induc
like
full
protect
homolog
heterolog
rout
mucos
mvtt
challeng
figur
sought
determin
whether
protect
would
appli
system
rout
viral
challeng
purpos
anoth
three
group
vttvaccin
mice
challeng
mvtt
via
im
rout
also
six
month
postvaccin
similarli
detect
level
anti
nab
found
three
week
first
mvtt
challeng
suggest
protect
role
vttinduc
immun
howev
found
second
mvtt
challeng
abl
gener
substanti
level
anti
nab
three
group
figur
sinc
level
anti
nab
valu
lower
three
vaccin
group
compar
placebo
nonvaccin
group
like
im
io
vaccin
confer
partial
signific
protect
mvtt
challeng
exampl
serum
dilut
factor
base
valu
via
differ
rout
prevaccin
placebo
io
im
respect
tabl
figur
sinc
substanti
level
antivtt
nab
respons
induc
one
time
vtt
vaccin
via
four
differ
rout
figur
b
puzzl
nab
abl
block
im
mvtt
infect
complet
reason
specul
might
differ
recal
antivtt
nab
respons
mvtt
challeng
therefor
measur
level
antivtt
nab
respons
two
mvtt
challeng
found
first
mvtt
challeng
boost
level
antivtt
nab
significantli
confirm
share
neutral
determin
vtt
figur
averag
serum
dilut
factor
antivaccinia
nab
among
im
io
vttvaccin
mice
reach
compar
level
valu
respect
statist
signific
figur
p
valu
calcul
averag
valu
antivtt
nab
first
challeng
three
group
im
averag
averag
io
averag
addit
determin
antivtt
nab
respons
second
challeng
mvtt
found
averag
serum
dilut
titer
antivtt
nab
among
im
io
prevttvaccin
mice
like
satur
compar
level
valu
respect
statist
signific
figur
b
p
valu
calcul
averag
valu
antivtt
nab
second
challeng
three
group
im
averag
averag
io
averag
appar
level
recal
antivtt
nab
suffici
block
complet
mucos
io
system
im
mvtt
challeng
suggest
like
differ
mucos
system
immun
smallpox
vaccin
involv
live
vaccinia
viru
remain
gold
standard
vaccin
led
complet
erad
deadli
human
viral
diseas
knowledg
studi
first
provid
parallel
experiment
comparison
four
differ
rout
vtt
vaccin
induc
protect
efficaci
mous
model
provid
evid
onetim
vaccin
vtt
four
differ
rout
abl
induc
longlast
antivaccinia
nab
respons
mice
appar
higher
level
nab
respons
induc
via
mucos
io
inocul
compar
im
sc
rout
moreov
io
vtt
vaccin
like
protect
anim
complet
two
consecut
mucos
challeng
mvtt
strain
via
either
homolog
io
heterolog
io
rout
respect
figur
control
sc
vtt
vaccin
achiev
full
protect
im
io
mvtt
challeng
respect
figur
b
im
vtt
vaccin
fulli
protect
anim
io
mvtt
challeng
im
io
vttvaccin
anim
fulli
protect
im
challeng
figur
result
therefor
suggest
rout
vtt
vaccin
critic
induc
protect
mice
meantim
find
im
mvtt
challeng
overcom
preexist
antivaccinia
immun
induc
via
mucos
rout
implic
mvttbase
mucos
vaccin
develop
rout
vtt
vaccin
determin
level
longlast
antivaccinia
nab
induc
demonstr
nab
induc
vaccinia
vaccin
play
essenti
role
provid
steril
immun
smallpox
infect
show
vtt
display
advantag
induc
higher
level
antivaccinia
nab
noninvas
mucos
rout
vaccin
underli
mechan
find
remain
larg
unknown
although
recent
provid
evid
tissu
tropism
may
play
role
affect
immunogen
vacciniabas
vaccin
sinc
vtt
variant
unlik
establish
longterm
persist
infect
mice
mechan
mainten
immunolog
memori
last
nab
remain
investig
one
studi
show
antigen
retain
drain
lymph
node
extend
period
time
whether
find
would
implic
continu
matur
vttinduc
nab
observ
studi
requir
futur
studi
acknowledg
differ
rout
vaccin
may
differ
protect
effect
conduct
direct
comparison
intraderm
id
vaccin
rout
id
vaccin
seem
induc
high
level
nab
previou
studi
howev
compar
skin
scarif
vaccin
rout
futur
studi
confer
steril
protect
human
smallpox
infect
histor
tradit
vv
challeng
model
involv
use
highli
pathogen
lethal
dose
virus
challeng
requir
special
biosafeti
contain
studi
develop
conveni
model
anim
challeng
base
test
antibodi
respons
highli
immunogen
protein
protocol
prepar
vaccinia
viru
mostli
intracellular
matur
virion
imv
particl
sinc
spike
protein
locat
imv
western
blot
analysi
data
shown
mvtt
particl
induc
sspecif
antibodi
unless
enter
cell
initi
infect
design
provid
anti
antibodi
valuabl
biolog
indic
protect
mvtt
challeng
mice
elimin
biosafeti
issu
relat
restrict
use
pathogen
vaccinia
wr
laboratori
regul
well
help
reduc
studi
cost
nonpathogen
viral
challeng
model
previous
use
studi
neutral
antibodymedi
protect
immunodefici
viral
infect
howev
recogn
limit
experiment
system
might
major
differ
lethal
nonpathogen
vaccinia
challeng
system
exampl
nktcell
ctl
togeth
nab
may
involv
protect
highli
pathogen
viru
issu
studi
futur
studi
mucos
vtt
vaccin
elicit
protect
homolog
heterolog
rout
mucos
mvtt
challeng
result
provid
scientif
evid
mucos
vtt
vaccin
eg
one
time
io
vtt
vaccin
studi
like
confer
complet
protect
mucos
rout
viral
challeng
figur
consist
previou
find
find
relev
smallpox
prevent
vaccin
like
provid
protect
barrier
domin
portal
variola
viral
entri
mucosa
conclud
fact
transmiss
smallpox
occur
mainli
inhal
airborn
variola
viru
usual
droplet
express
oral
nasal
pharyng
mucosa
infect
person
critic
role
mucos
immun
smallpox
vaccin
demonstr
previou
studi
sinc
four
group
mice
develop
system
antivaccinia
nab
mvtt
challeng
figur
c
specul
higher
level
nab
respons
induc
via
mucos
io
inocul
compar
sc
rout
might
play
role
block
mvtt
challeng
complet
end
rapidli
recal
high
level
antivtt
nab
mvtt
challeng
might
also
contribut
protect
figur
spite
find
extra
attent
paid
vtt
use
human
smallpox
vaccin
mucos
vaccin
due
vivo
toxic
virul
well
complic
quasispeci
contain
group
viral
variant
substitut
evid
use
safe
attenu
homogen
mvtt
strain
conduct
mucos
smallpox
vaccin
one
obstacl
applic
vacciniabas
vaccin
preexist
antivector
immun
often
issu
clinic
develop
vacciniabas
vaccin
previou
studi
indic
mucos
vaccin
overcom
preexist
antivaccinia
immun
gener
skin
vaccin
consist
show
io
mvtt
challeng
overcam
preexist
antivaccinia
immun
gener
sc
vtt
vaccin
induc
anti
nab
figur
b
moreov
provid
new
find
im
mvtt
challeng
overcom
preexist
antivaccinia
immun
gener
sc
io
rout
vtt
vaccin
figur
find
implic
either
overcom
preexist
antivaccinia
immun
improv
immunogen
vacciniabas
vaccin
sinc
vacciniabas
vaccin
develop
induc
protect
immun
respons
mucos
site
viral
transmiss
hiv
pathogen
find
provid
evid
support
new
strategi
heterolog
rout
prime
boost
vaccin
use
vaccin
comparison
heterolog
prime
boost
regimen
use
differ
viral
vector
area
interest
investig
one
limit
studi
lack
measur
tcellmedi
immun
besid
nab
possibl
observ
vttinduc
protect
partial
contribut
cellmedi
immun
end
mucos
rout
vaccin
may
also
crucial
gener
highli
protect
tcellmedi
immun
recent
studi
demonstr
protect
lethal
respiratori
vaccinia
challeng
requir
respiratori
mucos
tem
cell
central
memori
cell
futur
studi
therefor
necessari
address
protect
effect
specif
cellmedi
immun
similar
experiment
condit
